A Phase 4 interventional study of Peg-Interferon Alpha-2A and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 17 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-16.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies testing ribavirin in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ribavirin · Hepatitis C, Chronic.
Among the 175 studies testing ribavirin in Hepatitis C, Chronic, this one is the 64th largest by enrollment of the 174 interventional ones that give a count, is one of 17 that started in 2005, is one of 55 in phase 4, and was the 163rd registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 175 studies testing ribavirin in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 43 · Phase 3 66 · Phase 4 55
First in 1997; this study’s year is marked. 17 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 107 across the 174 interventional studies. Of the 159 that completed or were terminated, 87 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 175 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 26th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2005, is one of 29 in phase 4, and was the 82nd registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 175 studies testing ribavirin in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up in participants with Genotype 1 chronic hepatitis C (CHC), co-infected with human immunodeficiency virus type 1 (HIV-1).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
Drug: Peg-Interferon Alpha-2A · Drug: Ribavirin
Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
Drug: Peg-Interferon Alpha-2A · Drug: Ribavirin
Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
Also known as: Pegasys, Peg-IFN-Alpha-2A
Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (\>/=) 75 kg.
Percentage of Participants With Sustained Virologic Response (SVR)
SVR was defined as having un-detectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 International Units per milliliter \[IU/mL\]). Participants with detectable HCV RNA or without measurement at the end of the 24 week after completion of study treatment were considered as non-responders.
Time frame: 24 weeks after completion of study treatment (up to Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 96 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)
Percentage of Participants With Undetectable HCV RNA
HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Data for this outcome measure was to be reported up to end of treatment visit (Week 48 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, and 48; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, and 72
Percentage of Participants With Undetectable HCV RNA 12 Weeks After the Last Dose of Peg-IFN-Alpha-2A
HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Participants with detectable HCV RNA or without measurement at the end of 12 weeks after the last dose of Peg-IFN-Alpha-2A were considered as non-responders.
Time frame: 12 weeks after the last dose of Peg-IFN-Alpha-2A (up to Week 60 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 84 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)
Percentage of Participants Without SVR Among Participants With Undetectable HCV RNA at the End of Treatment
SVR was defined as having undetectable HCV RNA levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Percentage of participants without SVR among participants with undetectable HCV RNA at the end of treatment was reported (end of treatment = Week 48 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm).
Time frame: 24 weeks after completion of study treatment (up to Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 96 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)
Serum Human Immunodeficiency Virus (HIV) RNA Levels
HIV RNA levels were measured using Roche AMPLICOR MONITOR HIV-1 Test (limit of detection: 400 HIV-1 RNA copies/mL). Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, 72, and 96
Change From Baseline in Cluster of Differentiation (CD) 4 (CD4) Cell Counts at Weeks 4, 12, 24, 48, 72, and 96
Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, 72, and 96
Change From Baseline in CD4/CD8 Ratio at Weeks 4, 12, 24, 48, 72, and 96
Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, 72, and 96
Percentage of Participants With Alanine Aminotransferase (ALT) Level Categories
ALT levels were classified as: Normal Limit (NL) (as per laboratory standard), \>1-2 Upper Normal Limit (ULN), \>2-5 ULN, \>5-10 ULN, and \>10 ULN. Percentage of participants in each of these ALT level categories was reported. Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, 72, and 96
| Milestone | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Started | 90 | 90 |
| Treated | 82 | 86 |
| Completed | 63 | 58 |
| Not completed | 27 | 32 |
| Withdrew: Adverse event/intercurrent illness | 7 | 5 |
| Withdrew: Insufficient therapeutic response | 2 | 7 |
| Withdrew: Failure to return | 2 | 4 |
| Withdrew: Did not cooperate/refused treatment | 2 | 4 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Randomized but not treated | 8 | 4 |
SVR was defined as having un-detectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 International Units per milliliter \[IU/mL\]). Participants with detectable HCV RNA or without measurement at the end of the 24 week after completion of study treatment were considered as non-responders.
| percentage of participants | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) | 23.8 (15.0 to 34.6) | 36.5 (26.3 to 47.6) |
HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Data for this outcome measure was to be reported up to end of treatment visit (Week 48 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
| percentage of participants | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Week 4 (n=73, 83) | 2.7 (0.3 to 9.6) | 12.0 (5.9 to 21.0) |
| Week 12 (n=73, 81) | 23.3 (14.2 to 34.7) | 28.4 (18.9 to 39.5) |
| Week 24 (n=73, 78) | 52.1 (40.0 to 63.9) | 53.8 (42.2 to 65.2) |
| Week 48 (n=68, 71) | 55.9 (43.3 to 67.9) | 64.8 (52.5 to 75.8) |
| Week 72 (n=0, 65) | NA (NA to NA) | 56.9 (44.0 to 69.2) |
HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Participants with detectable HCV RNA or without measurement at the end of 12 weeks after the last dose of Peg-IFN-Alpha-2A were considered as non-responders.
| percentage of participants | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Percentage of Participants With Undetectable HCV RNA 12 Weeks After the Last Dose of Peg-IFN-Alpha-2A | 23.8 (15.0 to 34.6) | 36.5 (26.3 to 47.6) |
SVR was defined as having undetectable HCV RNA levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Percentage of participants without SVR among participants with undetectable HCV RNA at the end of treatment was reported (end of treatment = Week 48 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm).
| percentage of participants | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Percentage of Participants Without SVR Among Participants With Undetectable HCV RNA at the End of Treatment | 52.6 | 24.3 |
HIV RNA levels were measured using Roche AMPLICOR MONITOR HIV-1 Test (limit of detection: 400 HIV-1 RNA copies/mL). Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
| Log10 copies per milliliter | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Baseline (n=12, 23) | 4.23 ± 0.82 | 4.64 ± 0.74 |
| Week 4 (n=6, 16) | 3.94 ± 0.38 | 3.98 ± 0.69 |
| Week 24 (n=9, 20) | 3.96 ± 0.36 | 4.21 ± 0.72 |
| Week 48 (n=11, 17) | 4.02 ± 0.65 | 4.41 ± 0.75 |
| Week 72 (n=10, 9) | 4.08 ± 0.78 | 4.51 ± 0.85 |
| Week 96 (n=0, 13) | NA ± NA | 4.22 ± 0.85 |
Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
| Cells per cubic millimeter (cells/mm^3) | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Baseline (n=78, 81) | 578.7 ± 277.1 | 546.2 ± 278.8 |
| Change at Week 4 (n=69, 74) | -148.2 ± 197.5 | -88.0 ± 154.9 |
| Change at Week 12 (n=68, 75) | -185.4 ± 192.7 | -164.5 ± 193.9 |
| Change at Week 24 (n=69, 68) | -206.7 ± 217.0 | -178.4 ± 207.5 |
| Change at Week 48 (n=61, 67) | -209.4 ± 242.4 | -196.4 ± 226.4 |
| Change at Week 72 (n=58, 55) | 9.5 ± 188.9 | -167.5 ± 235.8 |
| Change at Week 96 (n=0, 62) | NA ± NA | -15.1 ± 212.2 |
Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
| Ratio | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Baseline (n=78, 81) | 0.67 ± 0.39 | 0.68 ± 0.44 |
| Change at Week 4 (n=69, 74) | 0.11 ± 0.42 | 0.09 ± 0.21 |
| Change at Week 12 (n=68, 75) | 0.22 ± 0.31 | 0.20 ± 0.27 |
| Change at Week 24 (n=69, 68) | 0.36 ± 0.51 | 0.29 ± 0.30 |
| Change at Week 48 (n=61, 67) | 0.43 ± 0.47 | 0.30 ± 0.43 |
| Change at Week 72 (n=58, 55) | 0.12 ± 0.41 | 0.36 ± 0.43 |
| Change at Week 96 (n=0, 62) | NA ± NA | 0.09 ± 0.35 |
ALT levels were classified as: Normal Limit (NL) (as per laboratory standard), \>1-2 Upper Normal Limit (ULN), \>2-5 ULN, \>5-10 ULN, and \>10 ULN. Percentage of participants in each of these ALT level categories was reported. Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).
| percentage of participants | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Week 4, NL (n=70, 78) | 50.0 | 52.6 |
| Week 4, >1-2 ULN (n=70, 78) | 40.0 | 38.5 |
| Week 4, >2-5 ULN (n=70, 78) | 10.0 | 9.0 |
| Week 4, >5-10 ULN (n=70, 78) | 0.0 | 0.0 |
| Week 4, >10 ULN (n=70, 78) | 0.0 | 0.0 |
| Week 12, NL (n=76, 77) | 61.8 | 62.3 |
| Week 12, >1-2 ULN (n=76, 77) | 27.6 | 29.9 |
| Week 12, >2-5 ULN (n=76, 77) | 10.5 | 5.2 |
| Week 12, >5-10 ULN (n=76, 77) | 0.0 | 1.3 |
| Week 12, >10 ULN (n=76, 77) | 0.0 | 1.3 |
| Week 24, NL (n=74, 74) | 70.3 | 63.5 |
| Week 24, >1-2 ULN (n=74, 74) | 27.0 | 28.4 |
| Week 24, >2-5 ULN (n=74, 74) | 2.7 | 6.8 |
| Week 24, >5-10 ULN (n=74, 74) | 0.0 | 0.0 |
| Week 24, >10 ULN (n=74, 74) | 0.0 | 1.4 |
| Week 48, NL (n=65, 71) | 67.7 | 69.0 |
| Week 48, >1-2 ULN (n=65, 71) | 24.6 | 26.8 |
| Week 48, >2-5 ULN (n=65, 71) | 7.7 | 2.8 |
| Week 48, >5-10 ULN (n=65, 71) | 0.0 | 1.4 |
| Week 48, >10 ULN (n=65, 71) | 0.0 | 0.0 |
| Week 72, NL (n=59, 61) | 52.5 | 68.9 |
| Week 72, >1-2 ULN (n=59, 61) | 27.1 | 27.9 |
| Week 72, >2-5 ULN (n=59, 61) | 20.3 | 3.3 |
| Week 72, >5-10 ULN (n=59, 61) | 0.0 | 0.0 |
| Week 72, >10 ULN (n=59, 61) | 0.0 | 0.0 |
| Week 96, NL (n=0, 62) | NA | 50.0 |
| Week 96, >1-2 ULN (n=0, 62) | NA | 35.5 |
| Week 96, >2-5 ULN (n=0, 62) | NA | 12.9 |
| Week 96, >5-10 ULN (n=0, 62) | NA | 1.6 |
| Week 96, >10 ULN (n=0, 62) | NA | 0.0 |
Collected over 96 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | — | 7/82 (8.5%) | 79/82 (96.3%) |
| Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks | — | 12/86 (14%) | 81/86 (94.2%) |
| Event | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| Pneumonia NOSInfections and infestations | 1/82 | 0/86 |
| Postoperative infectionInfections and infestations | 1/82 | 0/86 |
| Respiratory tract infection NOSInfections and infestations | 1/82 | 1/86 |
| Diarrhoea NOSGastrointestinal disorders | 1/82 | 0/86 |
| Mouth ulcerationGastrointestinal disorders | 1/82 | 0/86 |
| HypothyroidismEndocrine disorders | 1/82 | 0/86 |
| Influenza like illnessGeneral disorders | 1/82 | 0/86 |
| Lip and/or oral cavity cancer NOSNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/82 | 0/86 |
| Pregnancy NOSPregnancy, puerperium and perinatal conditions | 1/82 | 0/86 |
| DepressionPsychiatric disorders | 1/82 | 0/86 |
| Event | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks |
|---|---|---|
| HeadacheNervous system disorders | 34/82 | 41/86 |
| MyalgiaMusculoskeletal and connective tissue disorders | 38/82 | 33/86 |
| Anaemia NOSBlood and lymphatic system disorders | 31/82 | 25/86 |
| PyrexiaGeneral disorders | 30/82 | 32/86 |
| AstheniaGeneral disorders | 23/82 | 30/86 |
| FatigueGeneral disorders | 26/82 | 27/86 |
| AnorexiaMetabolism and nutrition disorders | 25/82 | 22/86 |
| InsomniaPsychiatric disorders | 14/82 | 23/86 |
| NauseaGastrointestinal disorders | 21/82 | 20/86 |
| Vomiting NOSGastrointestinal disorders | 9/82 | 17/86 |
Intent-to-treat (ITT) analysis population included all randomized participants who receive at least one dose of any study medication and have at least one post-baseline efficacy assessment.
| Age, Continuous(years) | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks | Total |
|---|---|---|---|
| Mean | 42.3 ± 7.9 | 42.2 ± 8.4 | 42.3 ± 8.2 |
| Sex: Female, Male(Participants) | Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks | Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks | Total |
|---|---|---|---|
| Female | 31 | 26 | 57 |
| Male | 49 | 59 | 108 |
The record gives a start of Apr 2005, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 8 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribavirin